Breaking News, Financial News

Financial Reports: Baxter 1Q

Advate, Gammagard Liquid drive BioScience growth

Baxter 1Q12

1Q Revenues: $3.4 billion (+3%)

1Q Earnings: $588 million (+3%)

Comments: BioScience revenues grew 4% to $1.5 billion, driven by demand for Advate and Gammagard Liquid, while the Medical Products business was up 3% to $1.9 billion. In the BioScience unit, recombinants rose 4% to $533 million, antibody therapies were up 4% to $388 million, plasma proteins were up 3% to $316 million and regenerative medicine was up 10% to $154 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters